Please login to the form below

Not currently logged in
Email:
Password:

Cephalon gets green light for cancer pain drug in EU

The European Commission has granted marketing authorisation for Cephalon's cancer pain drug Effentora
The European Commission has granted marketing authorisation for Cephalon's cancer pain drug Effentora.

Effentora, a buccal tablet formulation of fentanyl, which is indicated for the treatment of breakthrough cancer pain (BTCP) can now be marketed in the 27 EU member states as well as Norway and Iceland.

Cephalon, a US-based biopharmaceutical company, is seeking to bolster its standing in the European healthcare market.

Alain Aragues, president of Cephalon Europe, said: "Cephalon continues to build its presence in Europe, the Middle East and Africa, and activities are ongoing to make Effentora available quickly in the EU member countries."

"We are committed to bring new medications to the European markets that address the needs of patients with cancer," he added.

15th April 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics